To induce genomic exon skipping in DMD patients’ muscle tissue, a proper delivery vehicle is needed to introduce CRISPR-Cas9 and sgRNA targeting the human dystrophin sequence. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.